secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2025-10-20T23:59:59+00:00
Accession:  0001193125-25-242912
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics reports 44% ORR in [212Pb]VMT-α-NET trial; cash $174.1M
--------------------------------------------------------------------------------

- Phase 1/2a data: 44% objective response rate (7/16) in Cohort 2 patients with SSTR2+ all tumors at median 41-week follow-up.
- No dose-limiting toxicities, treatment-related discontinuations, or Grade 4/5 adverse events observed across 55 treated patients.
- 14 of 16 Cohort 2 patients with SSTR2+ all tumors remain progression-free and on study (87.5%).
- Preliminary cash, cash equivalents and short-term investments ~$174.1M as of Sep 30, 2025, funding operations into late 2026.
- Initial efficacy data for additional 31 patients expected in 2026; company plans registration study based on emerging profile.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000119312525242912/0001193125-25-242912-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000119312525242912/catx-20251020.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-242912

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer